Abbott “Knolls” When To Quit: Large-Scale Mergers Not On Agenda, CEO Says
Executive Summary
Abbott's acquisition of Knoll has given the company enough "critical mass" to meet its pharmaceutical growth goals, Abbott CEO Miles White indicated during an investor call Jan. 16
You may also be interested in...
Abbott Predicts Arthritis Therapy Humira Will Top $1 Bil. In 2005
Abbott predicts Humira (adalimumab) sales will top $1 bil. worldwide in 2005
Abbott Predicts Arthritis Therapy Humira Will Top $1 Bil. In 2005
Abbott predicts Humira (adalimumab) sales will top $1 bil. worldwide in 2005
Abbott Expects Science To “Trump” Scale; Sees Industry In “Transformation”
Abbott's formula for navigating a period of "transformation" in the pharmaceutical industry includes focusing on therapeutic categories where science matters more than scale, CEO Miles White told the Merrill Lynch pharmaceutical and biotechnology conference Feb. 3 in New York